Enhanced with market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights, The Business Research Company’s 2026 market reports deliver more actionable and strategically valuable research.
Chronic Plaque Psoriasis Market Size, Value And Growth Trends Through 2030
The global market for chronic plaque psoriasis experienced robust expansion lately, projected to advance from $22.26 billion in 2025 to $23.83 billion in 2026, reflecting a compound annual growth rate of 7.1%. This historical growth trajectory was fueled by enhanced identification of autoimmune skin conditions, greater accessibility to topical treatments, heightened understanding of psoriasis management strategies, an increase in dermatology centers, and improved access to specialized pharmaceutical options.
The market for chronic plaque psoriasis is projected for substantial expansion in the upcoming years, anticipating a reach of $30.99 billion by 2030, reflecting a compound annual growth rate of 6.8%. This anticipated growth trajectory is fueled by several key factors including the accelerated development of advanced biologics, a greater uptake of oral immunomodulatory agents, the proliferation of precision dermatology methodologies, an elevated emphasis on treatment strategies centered around the patient, and increased financial backing for autoimmune disease investigations. Furthermore, within this forecast period, significant market dynamics will be shaped by the expanding utilization of biologic therapies, a surge in the application of targeted small molecule pharmaceuticals, a heightened focus on bespoke dermatological care, the broadening availability of oral treatment modalities, and an intensified commitment to achieving enduring disease management.
Download A Free Sample Report For Comprehensive Market Insights:
https://www.thebusinessresearchcompany.com/sample.aspx?id=20726&type=smp
Chronic Plaque Psoriasis Market Growth Drivers: What Factors Are Accelerating Expansion?
The chronic plaque psoriasis market is poised for expansion due to a surge in immune system malfunctions. Such dysfunctions occur when the body’s natural defenses operate improperly, making individuals more vulnerable to illnesses including infections, autoimmune conditions, and cancers. Contributing factors to this rise in immune system issues include inherited traits, environmental influences, inadequate nutrition, persistent stress, and a growing incidence of conditions like HIV and other autoimmune disorders. Managing chronic plaque psoriasis becomes crucial for addressing these immune system irregularities, as an overzealous immune response can lead to accelerated skin cell production, resulting in inflammation and the characteristic plaque formations. For illustration, as of February 2024, Arthritis Australia reported projections indicating that in 2025, approximately 212,136 males and 362,137 females will be affected by rheumatoid arthritis, with anticipations for these figures to ascend by 2040 to roughly 280,040 males and 479,828 females. Consequently, the escalating prevalence of immune system disorders is directly fueling the advancement of the chronic plaque psoriasis market.
Chronic Plaque Psoriasis Market Segment Analysis Highlighting Growth Areas
The chronic plaque psoriasis market covered in this report is segmented –
1) By Drug Class: Biologics, Small Molecule Drugs
2) By Route Of Administration: Injectable, Oral, Topical
3) By Distribution Channel: Hospital Pharmacy, Online Pharmacy, Retail Pharmacy
Subsegments:
1) By Biologics: Tumor Necrosis Factor (TNF) Inhibitors, Interleukin Inhibitors (IL-12, IL-23, IL-17, IL-22), T-Cell Inhibitors
2) By Small Molecule Drugs: Phosphodiesterase 4 (PDE4) Inhibitors, Janus Kinase (JAK) Inhibitors, Retinoids
Chronic Plaque Psoriasis Market Trends: What Is Shaping Future Industry Growth?
Key players within the chronic plaque psoriasis market are concentrating their efforts on pioneering therapeutic solutions, including IL-17A and IL-17F inhibitors, aiming to achieve progress in managing chronic plaque psoriasis. Therapies that specifically target IL-17A and IL-17F function by intercepting these pro-inflammatory cytokines, which are integral to the immune system’s response, thereby diminishing inflammation associated with autoimmune conditions like chronic plaque psoriasis. A significant development occurred in October 2023 when UCB S.A., a biopharmaceutical firm based in Belgium, revealed that the U.S. Food and Drug Administration (FDA) had granted approval for BIMZELX (bimekizumab-bkzx) to treat adult patients experiencing moderate to severe plaque psoriasis who are candidates for systemic or phototherapy. Bimekizumab stands out as the inaugural approved therapy for psoriasis engineered to specifically target and inhibit both interleukin 17A (IL-17A) and interleukin 17F (IL-17F), two crucial cytokines implicated in inflammatory pathways. This approval was substantiated by findings from three main Phase 3 studies—BE READY, BE VIVID, and BE SURE—which collectively evaluated the safety and effectiveness of bimekizumab in a cohort of 1,480 individuals diagnosed with moderate to severe plaque psoriasis.
Chronic Plaque Psoriasis Market Leading Companies: Who Holds Significant Market Presence?
Major companies operating in the chronic plaque psoriasis market are Pfizer Inc., Johnson & Johnson, AbbVie Inc., Bristol‑Myers Squibb Company, Novartis AG, Eli Lilly and Company, Amgen Inc., Dr Reddy’s Laboratories, Innovent Biologics Inc., Bio‑Thera Solutions, Celgene Corporation, Arcutis Biotherapeutics, LEO Pharma A/S, Sun Pharmaceutical Industries Ltd, AstraZeneca plc, Takeda Pharmaceutical Company Limited, Biocon Ltd, Stiefel Laboratories Inc, Regeneron Pharmaceuticals, Sanofi S.A., GSK plc, Merck & Co. Inc., UCB S.A., Roche Holding AG, Evelo Biosciences Inc, Biogen Inc.
Access The Complete Chronic Plaque Psoriasis Market Report:
https://www.thebusinessresearchcompany.com/report/chronic-plaque-psoriasis-global-market-report
Chronic Plaque Psoriasis Market Regional Analysis And Leading Geography
North Americawas the largest region in the chronic plaque psoriasis market in 2025. Asia-Pacificis expected to be the fastest-growing region in the forecast period. The regions covered in the chronic plaque psoriasis market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
